S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

Lifesci Capital Analyst Recommendations & Stock Picks

This page lists the most recent publicly-reported stock recommendations and ratings issued by analysts at Lifesci Capital. These ratings and price targets were collected from public media reports and are believed to be accurate, but cannot be verified with 100% certainty. MarketBeat and its parent company are in no way affiliated with or endorsed by Lifesci Capital.

MarketRank evaluates a company based on community opinion, dividend strength, institutional and insider ownership, earnings and valuation, and analysts forecasts.
Available with a MarketBeat All Access Subscription
MarketRank™Upgrade to All Access to use the All Ranks Filter
Media sentiment refers to the percentage of positive news stories versus negative news stories a company has received in the past week.
Available with a MarketBeat All Access Subscription
Media SentimentUpgrade to All Access to use the All Sentiments Filter
Analyst consensus is the average investment recommendation among Wall Street research analysts.
Available with a MarketBeat All Access Subscription
Analyst ConsensusUpgrade to All Access to use the All Ratings Filter
CompanyDateActionBrokerageAnalystRatingPrice TargetImpact on PriceDetailsActions
NNOX
Nano-X Imaging
11/17/2021Downgraded byLifesci CapitalAnalyst R. RakhitOutperform -> Market PerformLow
VTYX
Ventyx Biosciences
11/15/2021Reiterated byLifesci CapitalAnalyst S. SlutskyOutperformHigh
ALXO
ALX Oncology
11/4/2021Reiterated byLifesci CapitalAnalyst A. EverttsOutperformMedium
AGLE
Aeglea BioTherapeutics
11/5/2021Reiterated byLifesci CapitalAnalyst S. SlutskyOutperformLow
PYXS
Pyxis Oncology
11/2/2021Reiterated byLifesci CapitalAnalyst A. EverttsOutperformLow
RCKT
Rocket Pharmaceuticals
10/24/2021Reiterated byLifesci CapitalAnalyst P. DolezalOutperformLow
DRIO
DarioHealth
8/26/2021Reiterated byLifesci CapitalAnalyst R. RakhitOutperformHigh
VRDN
Viridian Therapeutics
8/24/2021Reiterated byLifesci CapitalAnalyst R. KatkhudaOutperformLow
LHDX
Lucira Health
8/13/2021Downgraded byLifesci CapitalAnalyst D. ShermanOutperform -> Market PerformMedium
LRMR
Larimar Therapeutics
8/4/2021Reiterated byLifesci CapitalAnalyst P. DolezalOutperformMedium
OLMA
Olema Pharmaceuticals
6/21/2021Reiterated byLifesci CapitalAnalyst A. EverttsOutperformHigh
NNOX
Nano-X Imaging
6/3/2021Reiterated byLifesci CapitalAnalyst R. RakhitOutperformHigh
VECT
VectivBio
5/4/2021Reiterated byLifesci CapitalAnalyst P. DolezalOutperformHigh
ADVM
Adverum Biotechnologies
4/29/2021Downgraded byLifesci CapitalAnalyst P. DolezalOutperform -> Market PerformHigh
ODT
Odonate Therapeutics
3/22/2021Downgraded byLifesci CapitalAnalyst A. EverttsOutperform -> Market PerformHigh
ELDN
Eledon Pharmaceuticals
3/18/2021Reiterated byLifesci CapitalAnalyst R. KatkhudaOutperformHigh
LHDX
Lucira Health
3/2/2021Reiterated byLifesci CapitalAnalyst D. ShermanOutperformHigh
COGT
Cogent Biosciences
1/4/2021Reiterated byLifesci CapitalAnalyst S. SlutskyOutperformN/A
CLDX
Celldex Therapeutics
11/17/2020Reiterated byLifesci CapitalAnalyst S. SlutskyOutperformHigh
BLU
BELLUS Health
11/12/2020Reiterated byLifesci CapitalAnalyst S. SlutskyOutperformMedium
TARS
Tarsus Pharmaceuticals
11/10/2020Reiterated byLifesci CapitalAnalyst P. DolezalOutperformMedium
SRRA
Sierra Oncology
11/6/2020Reiterated byLifesci CapitalAnalyst S. SlutskyOutperformLow
AVDL
Avadel Pharmaceuticals
11/9/2020Reiterated byLifesci CapitalAnalyst D. ShermanOutperformLow
CBIO
Catalyst Biosciences
11/5/2020Reiterated byLifesci CapitalAnalyst S. SlutskyOutperformHigh
ADVM
Adverum Biotechnologies
11/5/2020Reiterated byLifesci CapitalAnalyst P. DolezalOutperformMedium
IFRX
InflaRx
10/30/2020Reiterated byLifesci CapitalAnalyst S. SlutskyMarket PerformLow
ODT
Odonate Therapeutics
10/28/2020Reiterated byLifesci CapitalAnalyst A. EverttsOutperformLow
OYST
Oyster Point Pharma
10/27/2020Reiterated byLifesci CapitalAnalyst P. DolezalOutperformMedium
AGLE
Aeglea BioTherapeutics
10/23/2020Reiterated byLifesci CapitalAnalyst S. SlutskyOutperformMedium
ALLK
Allakos
10/22/2020Reiterated byLifesci CapitalAnalyst S. SlutskyOutperformLow
MEIP
MEI Pharma
10/21/2020Reiterated byLifesci CapitalAnalyst A. EverttsOutperformMedium
RCKT
Rocket Pharmaceuticals
10/16/2020Reiterated byLifesci CapitalAnalyst P. DolezalOutperformLow
INBX
Inhibrx
10/15/2020Reiterated byLifesci CapitalAnalyst A. EverttsOutperformMedium
IMVT
Immunovant
10/6/2020Reiterated byLifesci CapitalAnalyst S. SlutskyOutperformHigh
VYNE
VYNE Therapeutics
10/2/2020Reiterated byLifesci CapitalAnalyst P. DolezalOutperformHigh
CBAY
CymaBay Therapeutics
9/29/2020Reiterated byLifesci CapitalAnalyst P. DolezalOutperformMedium
ALXO
ALX Oncology
9/30/2020Reiterated byLifesci CapitalAnalyst A. EverttsOutperformLow
CRTX
Cortexyme
9/24/2020Reiterated byLifesci CapitalAnalyst D. ShermanOutperformHigh

MarketBeat Community Rating for Lifesci Capital

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  38 (Vote Outperform)
Underperform Votes:  37 (Vote Underperform)
Total Votes:  75
MarketBeat's community ratings are surveys of what our community members think about Lifesci Capital and other research firms. Vote "Outperform" if you believe Lifesci Capital's recommendations will outperform the S&P 500 over the long term. Vote "Underperform" if you believe Lifesci Capital's recommendations will underperform the S&P 500 over the long term. You may vote once every thirty days.

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.